PMC:6640909 / 58529-59298 JSONTXT

{"project":"TEST0","denotations":[{"id":"31100109-66-71-7502","span":{"begin":183,"end":184},"obj":"[\"26922275\"]"},{"id":"31100109-114-119-7503","span":{"begin":231,"end":232},"obj":"[\"28017351\"]"},{"id":"31100109-117-122-7504","span":{"begin":234,"end":235},"obj":"[\"22052901\"]"},{"id":"31100109-144-149-7505","span":{"begin":261,"end":262},"obj":"[\"25034795\"]"},{"id":"31100109-154-159-7506","span":{"begin":494,"end":495},"obj":"[\"29034592\"]"},{"id":"31100109-61-66-7507","span":{"begin":559,"end":560},"obj":"[\"27207191\"]"}],"text":"Patient evaluation and selection for LT-MCS as a therapy for advanced HF involves consideration of multiple factors. LT-MCS is associated with early and late risks of adverse events [3], substantial resource utilization and costs [4, 5], hospital readmissions [6] and the potential for considerable suffering for patients and families [7]. It is therefore crucial that patient selection achieves the greatest treatment effect possible by targeting patients with the highest benefit/risk ratio [8]. Current HF guidelines of the European Society of Cardiology [9] recommend the use of LT-MCS; however, selection criteria for evaluation of potential candidates are lacking. Nonetheless, extensive data are available that predict outcomes with and in the absence of LT-MCS."}

{"project":"MyTest","denotations":[{"id":"31100109-26922275-28905562","span":{"begin":183,"end":184},"obj":"26922275"},{"id":"31100109-28017351-28905563","span":{"begin":231,"end":232},"obj":"28017351"},{"id":"31100109-22052901-28905564","span":{"begin":234,"end":235},"obj":"22052901"},{"id":"31100109-25034795-28905565","span":{"begin":261,"end":262},"obj":"25034795"},{"id":"31100109-29034592-28905566","span":{"begin":494,"end":495},"obj":"29034592"},{"id":"31100109-27207191-28905567","span":{"begin":559,"end":560},"obj":"27207191"}],"namespaces":[{"prefix":"_base","uri":"https://www.uniprot.org/uniprot/testbase"},{"prefix":"UniProtKB","uri":"https://www.uniprot.org/uniprot/"},{"prefix":"uniprot","uri":"https://www.uniprot.org/uniprotkb/"}],"text":"Patient evaluation and selection for LT-MCS as a therapy for advanced HF involves consideration of multiple factors. LT-MCS is associated with early and late risks of adverse events [3], substantial resource utilization and costs [4, 5], hospital readmissions [6] and the potential for considerable suffering for patients and families [7]. It is therefore crucial that patient selection achieves the greatest treatment effect possible by targeting patients with the highest benefit/risk ratio [8]. Current HF guidelines of the European Society of Cardiology [9] recommend the use of LT-MCS; however, selection criteria for evaluation of potential candidates are lacking. Nonetheless, extensive data are available that predict outcomes with and in the absence of LT-MCS."}

{"project":"0_colil","denotations":[{"id":"31100109-26922275-7502","span":{"begin":183,"end":184},"obj":"26922275"},{"id":"31100109-28017351-7503","span":{"begin":231,"end":232},"obj":"28017351"},{"id":"31100109-22052901-7504","span":{"begin":234,"end":235},"obj":"22052901"},{"id":"31100109-25034795-7505","span":{"begin":261,"end":262},"obj":"25034795"},{"id":"31100109-29034592-7506","span":{"begin":494,"end":495},"obj":"29034592"},{"id":"31100109-27207191-7507","span":{"begin":559,"end":560},"obj":"27207191"}],"text":"Patient evaluation and selection for LT-MCS as a therapy for advanced HF involves consideration of multiple factors. LT-MCS is associated with early and late risks of adverse events [3], substantial resource utilization and costs [4, 5], hospital readmissions [6] and the potential for considerable suffering for patients and families [7]. It is therefore crucial that patient selection achieves the greatest treatment effect possible by targeting patients with the highest benefit/risk ratio [8]. Current HF guidelines of the European Society of Cardiology [9] recommend the use of LT-MCS; however, selection criteria for evaluation of potential candidates are lacking. Nonetheless, extensive data are available that predict outcomes with and in the absence of LT-MCS."}

{"project":"2_test","denotations":[{"id":"31100109-26922275-28905562","span":{"begin":183,"end":184},"obj":"26922275"},{"id":"31100109-28017351-28905563","span":{"begin":231,"end":232},"obj":"28017351"},{"id":"31100109-22052901-28905564","span":{"begin":234,"end":235},"obj":"22052901"},{"id":"31100109-25034795-28905565","span":{"begin":261,"end":262},"obj":"25034795"},{"id":"31100109-29034592-28905566","span":{"begin":494,"end":495},"obj":"29034592"},{"id":"31100109-27207191-28905567","span":{"begin":559,"end":560},"obj":"27207191"}],"text":"Patient evaluation and selection for LT-MCS as a therapy for advanced HF involves consideration of multiple factors. LT-MCS is associated with early and late risks of adverse events [3], substantial resource utilization and costs [4, 5], hospital readmissions [6] and the potential for considerable suffering for patients and families [7]. It is therefore crucial that patient selection achieves the greatest treatment effect possible by targeting patients with the highest benefit/risk ratio [8]. Current HF guidelines of the European Society of Cardiology [9] recommend the use of LT-MCS; however, selection criteria for evaluation of potential candidates are lacking. Nonetheless, extensive data are available that predict outcomes with and in the absence of LT-MCS."}